You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1336 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
Jan 2024
Regimen
Intent: Palliative, Adjuvant
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
Apr 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Jan 2024
Regimen
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Aug 2021
Regimen
Intent: Curative
Funding:
New Drug Funding Program
    Cetuximab and Radiation - Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Jul 2023

Pages